Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

Clinical Immunology

Volumn 166-167, Issue , 2016, Pages 48-58

  Murahashi, Mutsunori ^a   Hijikata, Yasuki ^a   Yamada, Kazunari ^a   Tanaka, Yoshihiro ^b   Kishimoto, Junji ^b   Inoue, Hiroyuki ^b   Marumoto, Tomotoshi ^b   Takahashi, Atsushi ^b   Okazaki, Toshihiko ^a   Takeda, Kazuyoshi ^c   Hirakawa, Masakazu ^a   Fujii, Hiroshi ^b   Okano, Shinji ^b   Morita, Masaru ^d   Baba, Eishi ^d   Mizumoto, Kazuhiro ^d   Maehara, Yoshihiko ^d   Tanaka, Masao ^d   Akashi, Koichi ^d   Nakanishi, Yoichi ^b   Yoshida, Koji ^e   Tsunoda, Takuya ^e   Tamura, Kazuo ^f   Nakamura, Yusuke ^e   Tani, Kenzaburo ^a,b   more..

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; Five peptide cancer vaccine; Regulatory T cells; Translational research

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; DEPDC1 PROTEIN; INTERLEUKIN 2; KOC1 PROTEIN; MPHOSPH1 PROTEIN; PEPTIDE VACCINE; PEPTIDES AND PROTEINS; TTK PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; URLC10 PROTEIN; ANTINEOPLASTIC AGENT; EPITOPE; HLA A24 ANTIGEN; HLA-A*24:02 ANTIGEN; PEPTIDE; SUBUNIT VACCINE;

ADULT; ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; BONE METASTASIS; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; LUNG CANCER; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; SOLID TUMOR; UTERINE CERVIX CANCER; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; LEUKOPENIA; LUNG NEOPLASMS; METABOLISM; NEOPLASMS; STOMACH NEOPLASMS; T LYMPHOCYTE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COLORECTAL NEOPLASMS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPITOPES; FEMALE; HLA-A24 ANTIGEN; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PEPTIDES; STOMACH NEOPLASMS; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 84964600396     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.03.015     Document Type: Article

References (47)

1. Finke L.H., Wentworth K., Blumenstein B., et al. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine 2007, 25(Suppl. 2):B97-B109.
2. Melero I., Gaudernack G., Gerritsen W., et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 2014, 11:509-524.
3. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
4. Garon E.B., Rizvi N.A., Hui R., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 2015, 372:2018-2028.
5. Rosenberg S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat. Rev. Clin. Oncol. 2011, 8:577-585.
6. Kochenderfer J.N., Rosenberg S.A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat. Rev. Clin. Oncol. 2013, 10:267-276.
7. Speiser D.E., Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin. Immunol. 2010, 22:144-154.
8. Singh-Jasuja H., Emmerich N.P., Rammensee H.G. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 2004, 53:187-195.
9. Barve M., Bender J., Senzer N., et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:4418-4425.
10. Ghiringhelli F., Menard C., Puig P.E., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 2007, 56:641-648.
11. Walter S., Weinschenk T., Stenzl A., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 2012, 18:1254-1261.
12. Shahabi V., Postow M.A., Tuck D., et al. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am. J. Clin. Oncol. 2015, 38:90-97.
13. Keicho N., Itoyama S., Kashiwase K., et al. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum. Immunol. 2009, 70:527-531.
14. Kono K., Mizukami Y., Daigo Y., et al. Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009, 100:1502-1509.
15. Kanehira M., Katagiri T., Shimo A., et al. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res. 2007, 67:3276-3285.
16. Kanehira M., Harada Y., Takata R., et al. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene 2007, 26:6448-6455.
17. BioGPS <>, 2016. http://://biogps.org/#goto=welcome.
18. Okada K., Fujiwara Y., Nakamura Y., et al. Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. J. Surg. Oncol. 2012, 105:780-785.
19. Suda T., Tsunoda T., Daigo Y., et al. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007, 98:1803-1808.
20. Obara W., Ohsawa R., Kanehira M., et al. Cancer peptide vaccine therapy developed from oncoantigens identified through genome-wide expression profile analysis for Bladder Cancer. Jpn. J. Clin. Oncol. 2012, 42:591-600.
21. Kono K., Iinuma H., Akutsu Y., et al. Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J. Transl. Med. 2012, 10:141.
22. Yasuda S., Tsuchiya I., Okada K., et al. Significant clinical response of advanced colon cancer to peptide vaccine therapy: a case report. Tokai J. Exp. Clin. Med. 2012, 37:57-61.
23. Aruga A., Takeshita N., Kotera Y. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer. Clin. Cancer Res. 2013, 19:2224-2231.
24. Allred D.C., Harvey J.M., Berardo M., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11:155-168.
25. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. 2002, 2:251-262.
26. Klebanoff C.A., Gattinoni L., Restifo N.P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 2006, 211:214-224.
27. Sistigu A., Viaud S., Chaput N., et al. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 2011, 33:369-383.
28. Lutsiak M.E., Semnani R.T., De Pascalis R., et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868.
29. Kiniwa Y., Miyahara Y., Wang H.Y., et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 2007, 13:6947-6958.
30. Jarnicki A.G., Lysaght J., Todryk S., Mills K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J. Immunol. 2006, 177:896-904.
31. Wang R.F. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Hum. Immunol. 2008, 69:811-814.
32. Joosten S.A., van Meijgaarden K.E., Savage N.D., et al. Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8029-8034.
33. Joosten S.A., Ottenhoff T.H. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum. Immunol. 2008, 69:760-770.
34. Traverso I., Fenoglio D., Negrini S., et al. Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells. Hum. Immunol. 2012, 73:207-213.
35. Koreth J., Matsuoka K., Kim H.T., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N. Engl. J. Med. 2011, 365:2055-2066.
36. Saadoun D., Rosenzwajg M., Joly F., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 2011, 365:2067-2077.
37. Rao B., Han M., Wang L., et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J. Transl. Med. 2011, 9:17.
38. Jonker D.J., O'Callaghan C.J., Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007, 357:2040-2048.
39. Suzuki E., Ikeda M., Okusaka T., et al. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother. Pharmacol. 2013, 71:1141-1146.
40. Hazama S., Nakamura Y., Takenouchi H., et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunologicalresponse, and clinical outcome. J. Transl. Med. 2014, 12:63.
41. Svane I.M., Pedersen A.E., Nikolajsen K., et al. Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2. Vaccine 2008, 26:4716-4724.
42. Nakagawa S., Kanda T., Kosugi S., Ohashi M., Suzuki T., Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J. Am. Coll. Surg. 2004, 198:205-211.
43. Mizumoto M., Sugahara S., Nakayama H., et al. Clinical results of proton-beam therapy for locoregionally advanced esophageal cancer. Strahlenther. Onkol. 2010, 186:482-488.
44. Vatner R.E., Cooper B.T., Vanpouille-Box C., et al. Combinations of immunotherapy and radiation in cancer therapy. Front Oncol. 2014, 28:325.
45. Zitvogel L., Apetoh L., Ghiringhelli F., et al. The anticancer immune response: indispensable for therapeutic success?. J. Clin. Invest. 2008, 118:1991-2001.
46. Zitvogel L., Kepp O., Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 2011, 8:151-160.
47. Martin S.D., Coukos G., Holt R.A., et al. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann. Oncol. 2015, 26:2367-2374.